Expertise in
24
conditions

Dr. Rakesh Gaur

Hematology | Oncology
Laboratory Corporation Of America-Stat Lab
9301 W 74th St Ste 100, 
Overland Park, KS 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
24
conditions
Laboratory Corporation Of America-Stat Lab
9301 W 74th St Ste 100, 
Overland Park, KS 

Overview

Rakesh Gaur is a Hematologist and an Oncologist practicing medicine in Overland Park, Kansas.

Dr. Gaur is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Lung Cancer, Myelodysplastic Syndrome (MDS), Pleuropulmonary Blastoma, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 86 clinical trials. Dr. Gaur is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MO

Hospital Affiliations

Adventhealth Shawnee Mission
Kansas City Orthopaedic Institute
Adventhealth South Overland Park, Inc
University Of Kansas Hospital
Adventhealth Ottawa

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Laboratory Corporation Of America-Stat Lab
9301 W 74th St Ste 100, Overland Park, KS 66204
Other Locations
Office
9100 W 74th St, Overland Park, KS 66204
Adventhealth Medical Group Hematology Oncology At Shawnee Mission
9100 W 74th St, Merriam, KS 66204

Additional Areas of Focus

Dr. Gaur has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

86 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

20 Total Publications

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
Journal: Cancer
Published: March 11, 2021
Similar Doctors
Expertise in
6
conditions
Dr. Alan S. Gamis
Hematology | Oncology
Expertise in
6
conditions
Dr. Alan S. Gamis
Hematology | Oncology
Referral may be required

Children's Mercy Kansas City

2401 Gillham Rd, 
Kansas City, MO 
 (8.6 miles away)
816-234-3265
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alan Gamis is a Hematologist and an Oncologist practicing medicine in Kansas City, Missouri. Dr. Gamis is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Childhood Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Leukemia, Acute Megakaryoblastic Leukemia, and Bone Marrow Transplant. Dr. Gamis is currently accepting new patients.

Expertise in
42
conditions
Dr. Marc S. Hoffmann
Hematology | Oncology
Expertise in
42
conditions
Dr. Marc S. Hoffmann
Hematology | Oncology
Referral may be required

The University Of Kansas Cancer Center Overland Park

12200 W 110th St, 
Overland Park, KS 
 (4.6 miles away)
Experience:
18+ years
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Marc Hoffmann is a Hematologist and an Oncologist practicing medicine in Overland Park, Kansas. He has been practicing medicine for over 18 years. Dr. Hoffmann is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration. Dr. Hoffmann is board certified in American Board Of Internal Medicine, Hematology - 2015. Dr. Hoffmann is currently accepting new patients.

Expertise in
64
conditions
Dr. Jacob P. Smeltzer
Hematology | Oncology
Expertise in
64
conditions
Dr. Jacob P. Smeltzer
Hematology | Oncology
Referral may be required

AdventHealth Medical Group Hematology Oncology At Shawnee Mission

9100 W 74th St, 
Merriam, KS 
 (0.1 miles away)
913-632-9100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jacob Smeltzer is a Hematologist and an Oncologist practicing medicine in Merriam, Kansas. Dr. Smeltzer is highly rated in 64 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Colorectal Cancer, Neuroendocrine Tumor, and Large-Cell Immunoblastic Lymphoma. Dr. Smeltzer is currently accepting new patients.

Frequently Asked Questions about Dr. Rakesh Gaur

How do I make an appointment with Dr. Rakesh Gaur?

You can book an appointment with Dr. Rakesh Gaur by calling their office at 913-632-9100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rakesh Gaur a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rakesh Gaur is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rakesh Gaur specialize in?

While Dr. Rakesh Gaur is a Hematology, they have specific expertise in Colorectal Cancer, Lung Cancer, and Myelodysplastic Syndrome (MDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Rakesh Gaur participate in research or clinical trials?

Yes. Dr. Rakesh Gaur has published 20 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Rakesh Gaur's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rakesh Gaur accept my insurance?

Dr. Rakesh Gaur accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 913-632-9100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gaur's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 82 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile